Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Plus Therapeutics (PSTV) Interest & Investment Income (2016 - 2025)

Plus Therapeutics has reported Interest & Investment Income over the past 15 years, most recently at $29000.0 for Q4 2025.

  • Quarterly Interest & Investment Income fell 46.3% to $29000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $116000.0 through Dec 2025, down 57.51% year-over-year, with the annual reading at $116000.0 for FY2025, 57.51% down from the prior year.
  • Interest & Investment Income was $29000.0 for Q4 2025 at Plus Therapeutics, down from $59000.0 in the prior quarter.
  • Over five years, Interest & Investment Income peaked at $120000.0 in Q2 2023 and troughed at $1000.0 in Q1 2025.
  • The 5-year median for Interest & Investment Income is $51000.0 (2023), against an average of $49947.4.
  • Year-over-year, Interest & Investment Income skyrocketed 860.0% in 2022 and then crashed 98.61% in 2025.
  • A 5-year view of Interest & Investment Income shows it stood at $5000.0 in 2021, then surged by 1360.0% to $73000.0 in 2022, then skyrocketed by 50.68% to $110000.0 in 2023, then plummeted by 50.91% to $54000.0 in 2024, then tumbled by 46.3% to $29000.0 in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Interest & Investment Income are $29000.0 (Q4 2025), $59000.0 (Q3 2025), and $27000.0 (Q2 2025).